{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:32:00Z","timestamp":1788877920847,"version":"build-2803163510"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81571632"],"award-info":[{"award-number":["81571632"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771309"],"award-info":[{"award-number":["81771309"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Pseudoprogression (PsP) mimics true early progression (TeP) in conventional imaging, which poses a diagnostic challenge in glioblastoma (GBM) patients who undergo standard concurrent chemoradiation (CCRT). This study aimed to investigate whether perioperative markers could distinguish and predict PsP from TeP in <jats:italic>de novo<\/jats:italic> isocitrate dehydrogenase (IDH) wild-type GBM patients.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> New or progressive gadolinium-enhancing lesions that emerged within 12 weeks after CCRT were defined as early progression. Lesions that remained stable or spontaneously regressed were classified as PsP, otherwise persistently enlarged as TeP. Clinical, radiological, and molecular information were collected for further analysis. Patients in the early progression subgroup were divided into derivation and validation sets (7:3, according to operation date).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Among 234 consecutive cases enrolled in this retrospective study, the incidences of PsP, TeP, and neither patterns of progression (nP) were 26.1% (61\/234), 37.6% (88\/234), and 36.3% (85\/234), respectively. In the early progression subgroup, univariate analysis demonstrated female (<jats:italic>OR<\/jats:italic>: 2.161, <jats:italic>P<\/jats:italic> = 0.026), gross total removal (GTR) of the tumor (<jats:italic>OR<\/jats:italic>: 6.571, <jats:italic>P<\/jats:italic> &amp;lt; 001), located in the frontal lobe (<jats:italic>OR<\/jats:italic>: 2.561, <jats:italic>P<\/jats:italic> = 0.008), non-subventricular zone (SVZ) infringement (<jats:italic>OR<\/jats:italic>: 10.937, <jats:italic>P<\/jats:italic> &amp;lt; 0.001), and methylated O-6-methylguanine-DNA methyltransferase (MGMT) promoter (mMGMTp) (<jats:italic>OR<\/jats:italic>: 9.737, <jats:italic>P<\/jats:italic> &amp;lt; 0.001) were correlated with PsP, while GTR, non-SVZ infringement, and mMGMTp were further validated in multivariate analysis. Integrating quantitative MGMTp methylation levels from pyrosequencing, GTR, and non-SVZ infringement showed the best discriminative ability in the random forest model for derivation and validation set (AUC: 0.937, 0.911, respectively). Furthermore, a nomogram could effectively evaluate the importance of those markers in developing PsP (C-index: 0.916) and had a well-fitted calibration curve.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Integrating those clinical, radiological, and molecular features provided a novel and robust method to distinguish PsP from TeP, which was crucial for subsequent clinical decision making, clinical trial enrollment, and prognostic assessment. By in-depth interrogation of perioperative markers, clinicians could distinguish PsP from TeP independent from advanced imaging.<\/jats:p>","DOI":"10.3389\/fonc.2021.627325","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T04:29:42Z","timestamp":1618892982000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological, and Molecular Features"],"prefix":"10.3389","volume":"11","author":[{"given":"Mingxiao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gehong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuzhe","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kefu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41583-018-0014-3","article-title":"A glial blueprint for gliomagenesis","volume":"19","author":"Laug","year":"2018","journal-title":"Nat Rev Neurosci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0140-6736(18)30990-5","article-title":"Primary brain tumours in adults","volume":"392","author":"Lapointe","year":"2018","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","article-title":"Modified criteria for radiographic response assessment in glioblastoma clinical trials","volume":"14","author":"Ellingson","year":"2017","journal-title":"Neurotherapeutics."},{"key":"B4","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S1470-2045(08)70125-6","article-title":"Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas","volume":"9","author":"Brandsma","year":"2008","journal-title":"Lancet Oncology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1200\/JCO.2007.14.8163","article-title":"MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients","volume":"26","author":"Brandes","year":"2008","journal-title":"J Clin Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"6828396","DOI":"10.1155\/2018\/6828396","article-title":"Radiation necrosis, pseudoprogression, pseudoresponse, and tumor recurrence: imaging challenges for the evaluation of treated gliomas","volume":"2018","author":"Zikou","year":"2018","journal-title":"Contrast Media Mol Imaging."},{"key":"B7","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s11060-015-2001-0","article-title":"Pseudoprogression in glioblastoma patients: the impact of extent of resection","volume":"126","author":"Park","year":"2016","journal-title":"J Neurooncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1080\/14737175.2017.1375405","article-title":"Pseudoprogression after glioma therapy: an update","volume":"17","author":"Galldiks","year":"2017","journal-title":"Expert Rev Neurother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3171\/2018.12.JNS182775","article-title":"Proliferation-dominant high-grade astrocytoma: survival benefit associated with extensive resection of FLAIR abnormality region","volume":"132","author":"Jiang","year":"2019","journal-title":"J Neurosurg."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1200\/JCO.2010.30.0582","article-title":"Scale to predict survival after surgery for recurrent glioblastoma multiforme","volume":"28","author":"Park","year":"2010","journal-title":"J Clin Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11060-014-1478-2","article-title":"Identifying the survival subtypes of glioblastoma by quantitative volumetric analysis of MRI","volume":"119","author":"Zhang","year":"2014","journal-title":"J Neurooncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1093\/neuonc\/nor133","article-title":"Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance","volume":"13","author":"Kuhnt","year":"2011","journal-title":"Neuro Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s11060-018-03086-8","article-title":"Supratentorial high-grade astrocytoma with leptomeningeal spread to the fourth ventricle: a lethal dissemination with dismal prognosis","volume":"142","author":"Li","year":"2019","journal-title":"J Neurooncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s11060-013-1332-y","article-title":"Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients","volume":"116","author":"Quillien","year":"2014","journal-title":"J Neurooncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"188","DOI":"10.21147\/j.issn.1000-9604.2019.01.14","article-title":"Prognostic implications of epidermal growth factor receptor variant III expression and nuclear translocation in Chinese human gliomas","volume":"31","author":"Yang","year":"2019","journal-title":"Chin J Cancer Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","article-title":"Glioma groups based on 1p\/19q, IDH, and TERT promoter mutations in tumors","volume":"372","author":"Eckel-Passow","year":"2015","journal-title":"N Engl J Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11060-015-1774-5","article-title":"Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard?","volume":"123","author":"Melguizo-Gavilanes","year":"2015","journal-title":"J Neurooncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"113080","DOI":"10.3390\/cancers12113080","article-title":"A preliminary study on machine learning-based evaluation of static and dynamic FET-PET for the detection of pseudoprogression in patients with IDH-wildtype glioblastoma","volume":"12","author":"Kebir","year":"2020","journal-title":"Cancers."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.3389\/fonc.2019.01134","article-title":"Contribution of different positron emission tomography tracers in glioma management: focus on glioblastoma","volume":"9","author":"Moreau","year":"2019","journal-title":"Front Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nic.2020.09.010","article-title":"Imaging glioblastoma posttreatment: progression, pseudoprogression, pseudoresponse, radiation necrosis","volume":"31","author":"Strauss","year":"2021","journal-title":"Neuroimaging Clin N Am."},{"key":"B23","doi-asserted-by":"publisher","first-page":"944","DOI":"10.3174\/ajnr.A3324","article-title":"Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis","volume":"34","author":"Nihashi","year":"2013","journal-title":"Am J Neuroradiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1007\/s00330-017-4789-9","article-title":"Diagnostic accuracy of magnetic resonance imaging techniques for treatment response evaluation in patients with high-grade glioma, a systematic review and meta-analysis","volume":"27","author":"van Dijken","year":"2017","journal-title":"Eur Radiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/jmri.26171","article-title":"Pseudoprogression of brain tumors","volume":"48","author":"Thust","year":"2018","journal-title":"J Magn Reson Imaging."},{"key":"B26","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2217\/fon-2017-0437","article-title":"MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme","volume":"14","author":"Gurrieri","year":"2018","journal-title":"Future Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s11060-018-2981-7","article-title":"Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme","volume":"140","author":"De Carlo","year":"2018","journal-title":"J Neurooncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/cns.13040","article-title":"Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas","volume":"25","author":"Chai","year":"2019","journal-title":"CNS Neurosci Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"437","DOI":"10.21873\/cgp.20102","article-title":"MGMT gene promoter methylation status \u2013 assessment of two pyrosequencing kits and three methylation-specific PCR methods for their predictive capacity in glioblastomas","volume":"15","author":"Johannessen","year":"2018","journal-title":"Cancer Genom Proteom."},{"key":"B30","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11060-020-03556-y","article-title":"A systematic review and meta-analysis of supratotal vs. gross total resection for glioblastoma","volume":"148","author":"Jackson","year":"2020","journal-title":"J Neurooncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.wneu.2019.04.092","article-title":"Association between supratotal glioblastoma resection and patient survival: a systematic review and meta-analysis","volume":"127","author":"Incekara","year":"2019","journal-title":"World Neurosurg."},{"key":"B32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/neuonc\/nos268","article-title":"Relationship of glioblastoma multiforme to the subventricular zone is associated with survival","volume":"15","author":"Jafri","year":"2013","journal-title":"Neuro Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13014-017-0791-2","article-title":"Subventricular zones: new key targets for glioblastoma treatment","volume":"12","author":"Khalifa","year":"2017","journal-title":"Radiat Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ijrobp.2013.02.014","article-title":"Increased subventricular zone radiation dose correlates with survival in glioblastoma patients after gross total resection","volume":"86","author":"Chen","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B35","first-page":"845","article-title":"Neural precursor-derived pleiotrophin mediates subventricular zone invasion by glioma","volume-title":"Cell.","author":"Qin","year":"2017"},{"key":"B36","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/neuonc\/now136","article-title":"CXCL12 mediates glioblastoma resistance to radiotherapy in the subventricular zone","volume":"19","author":"Goffart","year":"2017","journal-title":"Neuro-Oncology."},{"key":"B37","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12916-016-0710-7","article-title":"Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone","volume":"14","author":"Jungk","year":"2016","journal-title":"BMC Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N Engl J Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA."}],"updated-by":[{"DOI":"10.3389\/fonc.2021.700599","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000}}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.627325\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T13:38:27Z","timestamp":1621431507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.627325\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":39,"alternative-id":["10.3389\/fonc.2021.627325"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.627325","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fonc.2021.700599","asserted-by":"object"}]},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,20]]},"article-number":"627325"}}